The drug repositioning Market is attracting major pharmaceutical companies as established medicines become increasingly valuable assets for exploring new therapeutic opportunities. WiseGuyReports profiles companies including Novartis, Pfizer, Merck, Bayer, Eli Lilly, Bristol Myers Squibb, Roche, Teva Pharmaceuticals, Amgen, Johnson & Johnson, Regeneron Pharmaceuticals, GSK, AbbVie, Sanofi, and AstraZeneca.

Competition is increasingly focused on research efficiency, data capabilities, therapeutic expertise, and access to innovative discovery technologies. Companies are looking for ways to identify promising repositioning candidates while improving the efficiency of research and development programs.

Strategic collaborations are an important part of this competitive environment. The report highlights AI-focused partnerships and collaborations involving pharmaceutical companies and technology organizations as examples of how the industry is combining pharmaceutical expertise with advanced computational capabilities.

Opportunities are extending beyond established therapeutic areas. Rare diseases, personalized medicine, cost-efficient development, and emerging regulatory pathways provide additional avenues for market expansion. Contract research organizations and academic institutions are also important participants because they contribute specialized research and development capabilities.

Looking ahead, the market is expected to benefit from continued advances in AI, real-world evidence, bioinformatics, and data analytics. These technologies may help companies identify new opportunities across oncology, neurology, cardiology, infectious diseases, and metabolic disorders.

With the global market projected to reach USD 25 billion by 2035, drug repositioning is likely to remain an important component of pharmaceutical innovation. Companies that combine strong portfolios with advanced analytics, strategic partnerships, and efficient research models may gain an advantage in this expanding market.